# Second Quarter / First Half Year Results 2023

Analyst presentation



## **Disclaimer**

This presentation contains certain statements that are neither reported financial results nor other historical information.

This presentation also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements.

Many of these risks and uncertainties relate to factors that are beyond Clariant's ability to control or estimate precisely, such as future market conditions, geopolitical dislocation, currency fluctuations, the behavior of other market participants, the actions of governmental regulators, and other risk factors, such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social, and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation, and consumer confidence, on a global, regional, or national basis.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document.

Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.



# Highlights Q2 / H1 2023

**Key Figures** 

1 084 m

Sales Q2 2023

78 m

Operating cash flow H1 2023

56 %

FCF conversion (June 2023 LTM<sup>1</sup>)

175 m

**EBITDA Q2 2023** 

75 m

Capex H1 2023


62 m

Preliminary gain on Quats divestment



## E


# Q2 sales: Strong Catalysts performance partially compensated for weak demand in Care Chemicals and Additives – FX impact from strong CHF



# **Geographic split**

### Q2 sales CHF 1084 m


in CHF m, % in local currency



# Regional headline

- Sales in the Americas declined, around half of which was due to the divestment of the North American Land Oil business. Volumes in Care Chemicals declined, while Adsorbents & Additives grew, mainly attributable to the Attapulgite integration
- EMEA sales declined as Care Chemicals and Adsorbents
   & Additives were lower, while Catalysts had strong sales
   in the Middle-East
- Asia-Pacific sales were stable, despite a decline in China, as growth in Catalysts (price and volume)
   balanced out lower prices and volumes observed by Care Chemicals and Adsorbents & Additives

# Q2 profitability: Catalysts improvement and Quats gain compensate negative operating leverage (volume) and inventory devaluation



# **Second Quarter 2023 Strategic Priorities**

### - Podari sunliquid®


- Negative operational EBITDA impact of CHF 10 m in Q2 2023
- Sequentially similar level in Q3 2023 expected
- Continued efforts to address ramp-up challenges in Podari
- Restructuring charges of CHF 7 m in Q2 2023 to focus biotechnology activities and adjustments of cost structure
- Actively evaluating strategic options for sunliquid® update by end of 2023.

### Performance programs

- Increased cost savings target by CHF 10 m with focus on aligning our cost base to a low volume environment
- On track for revised 2025 targeted savings of CHF 170 m, achieved CHF 107 m savings as of Q2 2023
- CHF 14 m additional savings delivered in Q2 2023 across the performance programs in the business units and corporate


### Portfolio optimization

- Closing of Quats divestment on 1 June 2023
- Preliminary gain on disposal of CHF 62 m



# Continued progress on path to 2030 greenhouse gas (GHG) target


Reducing our carbon footprint...



Scope 1 & 2 GHG emissions

in m tCO<sub>2</sub>e, corresponding to - 17 % since 2019


...and the carbon footprint of our raw materials



Scope 3 GHG emissions from purchased goods and services in m tCO<sub>2</sub>e, corresponding to - 15 % since 2019

<sup>1</sup> Last Twelve Months (Q3 2022 - Q2 2023)

# ESG update – Q2 2023 milestones / examples








# Second Quarter 2023 Care Chemicals

in CHF m	Q2 2023	Q2 2022	% CHF	% LC¹
Sales	543	740	- 27	- 17
EBITDA	133	142	- 6	
EBITDA margin	24.5 %	19.2 %		
EBITDA b.e.i. <sup>2</sup>	77	140	- 45	
EBITDA b.e.i. <sup>2</sup> margin	14.2 %	18.9 %		

	Q2 2023
Volumes	- 10 %
Price	- 2 %
Currency	- 10 %
Scope	- 5 %
· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·



# **Highlights**


- Volume declined versus high comparison base due to weak demand, prolonged destocking, and scope
- Pricing slightly lower due to formula-based price adjustments linked to raw material prices
- Segments: Oil Services grew at a high single-digit percentage rate; Personal & Home Care declined in midteen range, more pronounced declines in Crop Solutions and Industrial Applications
- Sales grew in Asia-Pacific, while all other regions declined
- EBITDA impacted by lower volumes that reduced operating leverage, inventory devaluation, as well as restructuring (CHF - 6 m), compensated by preliminary Quats divestment gain (CHF 62 m)

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# **Second Quarter 2023 Catalysts**

in CHF m	Q2 2023	Q2 2022	% CHF	% LC¹
Sales	277	232	19	30
EBITDA	42	13	223	
EBITDA margin	15.2 %	5.6 %		
EBITDA b.e.i. <sup>2</sup>	51	14	264	
EBITDA b.e.i. <sup>2</sup> margin	18.4 %	6.0 %		





# **Highlights**


- Volume growth in most segments, Propylene and Syngas
   & Fuels in particular continued positive pricing
- Segments: Strong growth in Propylene (> 50 %), followed by Syngas and Ethylene
- Project nature of business impacted regional dynamics;
   largest market Asia-Pacific up at mid-teen percentage
   rate due to CATOFIN<sup>®</sup>, which also drove EMEA sales
- EBITDA impacted by continued positive pricing, positive business mix, and higher volumes (operating leverage)
- sunliquid<sup>®</sup> effect
  - CHF 10 m operational impact (sequentially improved)
  - CHF 7 m bioethanol restructuring
- → 21.3 % EBITDA margin excluding sunliquid®

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# Second Quarter 2023 Adsorbents & Additives

in CHF m	Q2 2023	Q2 2022	% CHF	% LC¹
Sales	264	329	- 20	- 12
EBITDA	18	79	- 77	
EBITDA margin	6.8 %	24.0 %		
EBITDA b.e.i. <sup>2</sup>	25	80	- 69	
EBITDA b.e.i. <sup>2</sup> margin	9.5 %	24.3 %		

Q2 2023
- 17 %
+ 2 %
- 8 %
+ 3 %



# **Highlights**


 Volume declined significantly, driven by Additives; pricing slightly positive (value-based pricing)

### – Segments:

- Adsorbents up by a low-double-digit percentage rate (Purification and Foundry)
- Additives down by a low thirties-percent percentage rate against very strong comparison base, prolonged destocking and continued very weak demand in key end markets
- US Attapulgite contribution 3 % (scope)
- Americas up (US Attapulgite); EMEA and Asia down
- EBITDA impacted by lower operating leverage (Additives), business mix, inventory devaluation, and restructuring (CHF - 7 m)

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# On track to achieve total cost savings of CHF 170 m by 2025 – Q2 2023 delivered additional CHF 14 m savings



## 5

# First Half Year 2023

## **Key Figures**

2 284 m

Sales

342 m

**EBITDA** 

78 m

Operating cash flow

330 m

SG&A

230 m

Net result (continuing operations)

908 m

Net debt

# **Highlights**

- Sales decreased by 3 % in LC¹ (- 2 % organic in LC¹)
- Selling, general, and administrative costs (SG&A)
   declined by 20 % due to disposal proceeds and benefits
   from performance programs
- EBITDA declined by 22 %, resulting in a margin of 15.0 %
- Net result from continuing operations increased by 22 %, predominantly due to strong Catalysts business performance, preliminary gain from Quats disposal, and positive income tax
- Cash generated from operating activities increased by CHF 95 m due to active working capital management
- Group Net Debt increased due to reduced liquidity resulting from the payment of dividends




Outlook 2023

# Outlook 2023: Confirming adjusted outlook as of 7 July 2023

### 2023

Sales Range (CHF)

**EBITDA Range (CHF)** 



CHF 650 – 700 m

(margin 14.3 % – 15.1 %)

(5.2 b in 2022)

(margin 15.6 % in 2022)

### Confirmed commitment towards 2025 financial targets







Profitable sales growth (4 – 6 % CAGR)

Group EBITDA margin between 19 – 21 %

Free cash flow conversion of around 40 %

### **Internal Factors**

- Softening pricing in recessionary/deflationary economic environment
- Execute new operating model deliver restructuring savings
- Total top-line net impact of CHF 150 m (divestments/acquisition)
- Further improve sunliquid<sup>®</sup> performance
- Capex: targeted to CHF 220 m in 2023

### **External Factors**

- Soft recessionary environment expected in H2 2023
- Moderation in general inflation
- Currently limited indications for an economic recovery in H2 2023, uncertainties and risks remain
- China recovery at very slow pace
- Raw material and energy costs are easing, putting pressure on commercial selling prices





# **Second Quarter 2023 – Overview**

### Group

in CHF m	Q2 2023	Q2 2022	% CHF	% LC <sup>1</sup>
Sales	1 084	1 301	- 17	- 7
EBITDA	175	216	- 19	
EBITDA margin	16.1 %	16.6 %		
EBITDA b.e.i. <sup>2</sup>	135	210	- 36	
EBITDA b.e.i. <sup>2</sup> margin	12.5 %	16.1 %		
Sales Bridge	Price 0 %	<b>Volume</b> - 5 %	Currency - 10 %	<b>Scope</b> - 2 %

## **Catalysts**

in CHF m	Q2 2023	Q2 2022	% CHF	% LC <sup>1</sup>
Sales	277	232	19	30
EBITDA	42	13	223	
EBITDA margin	15.2 %	5.6 %		
EBITDA b.e.i. <sup>2</sup>	51	14	264	
EBITDA b.e.i. <sup>2</sup> margin	18.4 %	6.0 %		
Sales Bridge	<b>Price</b> + 5 %	<b>Volume</b> + 25 %	Currency - 11 %	<b>Scope</b> 0 %

**Care Chemicals** 

in CHF m	Q2 2023	Q2 2022	% CHF	% LC¹
Sales	543	740	- 27	- 17
EBITDA	133	142	- 6	
EBITDA margin	24.5 %	19.2 %		
EBITDA b.e.i. <sup>2</sup>	77	140	- 45	
EBITDA b.e.i. <sup>2</sup> margin	14.2 %	18.9 %		
Sales Bridge	<b>Price</b> - 2 %	<b>Volume</b> - 10 %	Currency - 10 %	<b>Scope</b> - 5 %

### **Adsorbents & Additives**

in CHF m	Q2 2023	Q2 2022	% CHF	% LC <sup>1</sup>
Sales	264	329	- 20	- 12
EBITDA	18	79	- 77	
EBITDA margin	6.8 %	24.0 %		
EBITDA b.e.i. <sup>2</sup>	25	80	- 69	
EBITDA b.e.i. <sup>2</sup> margin	9.5 %	24.3 %		
Sales Bridge	<b>Price</b> + 2 %	<b>Volume</b> - 17 %	Currency - 8 %	<b>Scope</b> + 3 %

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# First Half Year 2023 – Overview

### Group

in CHF m	H1 2023	H1 2022	% CHF	% LC <sup>1</sup>
Sales	2 284	2 563	- 11	- 3
EBITDA	342	436	- 22	
EBITDA margin	15.0 %	17.0 %		
EBITDA b.e.i. <sup>2</sup>	319	448	- 29	
EBITDA b.e.i. <sup>2</sup> margin	14.0 %	17.5 %		
Sales Bridge	<b>Price</b> + 4 %	<b>Volume</b> - 6 %	Currency - 8 %	<b>Scope</b> - 1 %

## **Catalysts**

in CHF m	H1 2023	H1 2022	% CHF	% LC <sup>1</sup>
Sales	482	417	16	25
EBITDA	55	27	104	
EBITDA margin	11.4 %	6.5 %		
EBITDA b.e.i. <sup>2</sup>	64	28	129	
EBITDA b.e.i. <sup>2</sup> margin	13.3 %	6.7 %		
Sales Bridge	<b>Price</b> + 5 %	<b>Volume</b> + 20 %	Currency - 9 %	Scope 0 %

**Care Chemicals** 

in CHF m	H1 2023	H1 2022	% CHF	% LC <sup>1</sup>
Sales	1 246	1 498	- 17	- 9
EBITDA	261	291	- 10	
EBITDA margin	20.9 %	19.4 %		
EBITDA b.e.i. <sup>2</sup>	207	291	- 29	
EBITDA b.e.i. <sup>2</sup> margin	16.6 %	19.4 %		
Sales Bridge	<b>Price</b> + 3 %	<b>Volume</b> - 9 %	Currency - 8 %	<b>Scope</b> - 3 %

### **Adsorbents & Additives**

in CHF m	H1 2023	H1 2022	% CHF	% LC <sup>1</sup>
Sales	556	648	- 14	- 8
EBITDA	72	162	- 56	
EBITDA margin	12.9 %	25.0 %		
EBITDA b.e.i. <sup>2</sup>	80	163	- 51	
EBITDA b.e.i. <sup>2</sup> margin	14.4 %	25.2 %		
Sales Bridge	<b>Price</b> + 5 %	<b>Volume</b> - 16 %	Currency - 6 %	<b>Scope</b> + 3 %

<sup>&</sup>lt;sup>1</sup> local currency; <sup>2</sup> before exceptional items

# First Half Year 2023 – Consolidated Income Statement

CHF m		2023		2022
	CHF m	%	CHF m	%
Sales	2'284	100.0	2'563	100.0
Costs of goods sold	-1'676	73.4	-1'805	70.4
Gross profit	608	26.6	758	29.6
Calling as a self-ord administrative costs	220	444	440	10.0
Selling, general, and administrative costs	-330	14.4	-410	16.0
Research and development	-78	3.4	-79	3.1
Income from associates and joint ventures	22	1.0	21	0.8
Operating result	222	9.8	290	11.3
<u>operaning</u> recair				
Finance income	13	0.6	8	0.3
Finance costs	-45	2.0	-44	1.7
Income before taxes	190	8.4	254	9.9
Taxes	40	1.8	-65	2.5
Net result from continuing operations	230	10.1	189	7.4
Net result from discontinued				
operations	2		197	
Net result total	232		386	

# **Highlights**

- Gross margin declined to 26.6 %, driven by lower volumes
- Selling, general, and administrative costs declined to CHF 330 m due to inclusion of disposal proceeds and benefits from performance programs
- R&D expenses remained stable year-on-year
- Operating result declined as a result of lower sales
- Tax income of CHF 40 million due to reassessment of provisions related to prior years
- Net result from continuing operations increased to CHF 230 m predominantly due to strong Catalysts business performance, preliminary gain from Quats disposal, and positive income tax

# First Half Year 2023 – Cash Flow Statement

		2022
232		386
120	137	
-	9	
11	_	
13	14	
-22	-21	
-40	63	
21	24	
-61	-24	
_	-198	
12	32	
54		36
38		35
-24		-17
300		440
-46		-264
40		-118
-176		7
34		7
-14		-30
138		42
-60		-59
78		-17
-74	-88	
•		
6	3	
1 9	8	
4	1	
_	579	
113	131	
251		380
-8	-4	
-138	_	
-13	-9	
32	40	
-256	-404	
-26	-26	
-18	-18	
-5	-6	
-432		-427
-6		1
-109		-63
394		415
285		352
	120 11 11 13 22 -40 21 -61 12  54 -8 -74 -1 -14 -14 -138 -60 -78 -74 -1 -16 -6 -6 -220 -1 -8 -138 -13 -13 -256 -26 -18 -5 -432 -6 -109	120 137 - 9 111 - 9 111 - 13

# **Highlights**

- Cash generated from operating activities increased significantly to CHF 78 m due to active working capital management
- Continued disciplined capex (property, plant, and equipment and intangible assets) of CHF 75 m
- Free Cash Flow (FCF¹) of CHF 3 m vs. CHF -106 m in the previous year
- FCF conversion (June 2023 LTM) of 56 %
- Net cash used in financing activities driven by annual distribution to shareholders and financial debt repayment

## First Half Year 2023 – Balance Sheet

		30.06.2023		31.12.2022
ASSETS	CHF m	%	CHF m	%
Noncurrent assets				
Property, plant, and equipment	1'503		1'549	
Right-of-use assets	242		240	
Intangible assets	968		997	
Investments in associates and joint ventures	244		327	
Financial assets	308		225	
Employee benefits	62		61	
Deferred income tax assets	132		120	
Total noncurrent assets	3'459	60.9	3'519	56.9
Current assets				
Inventories	804		796	
Trade receivables	666		725	
Other current assets	360		326	
Current income tax receivables	57		54	
Short-term deposits	45		324	
Cash and cash equivalents	285		394	
Total current assets	2'217	39.1	2'619	42.3
Assets held for sale	2	_	50	0.8
Total assets	5'678	100	6'188	100.0


- Total Assets decreased to CHF 5.7 bn mainly due to repayments of various certificates of indebtedness and disposals (North American Land Oil and Quats businesses)
- Investments in associates and JVs decreased to CHF 244 m due to change of Heubach stake consolidation method
- Group Net Debt increased to CHF 908 m due to reduced liquidity resulting from the payment of dividends

		30.06.2023		31.12.2022
EQUITY AND LIABILITIES	CHF m	%	CHF m	%
Equity	-			
Share capital	724		863	
Treasury shares (par value)	-7		-8	
Other reserves	-1'213		-1'165	
Retained earnings	2'867		2'651	
Total capital and reserves attributable to Clariant				
shareholders	2'371		2'341	
Noncontrolling interests	177		172	
Total equity	2'548	44.9	2'513	40.6
Liabilities				
Noncurrent liabilities				
Financial debts	760		870	
Deferred income tax liabilities	22		27	
Retirement benefit obligations	473		488	
Noncurrent lease liabilities	198		195	
Provision for noncurrent liabilities	171		178	
Other liabilities	52		55	
Total noncurrent liabilities	1'676	29.5	1'813	29.3
Current liabilities				
Trade payables and other liabilities	838		1'009	
Financial debts	237		355	
Current income tax liabilities	156		233	
Current lease liabilities	43		44	
Provision for current liabilities	180		215	
Total current liabilities	1'454	25.6	1'856	30.0
Liabilities directly associated with assets held for sale	_	_	6	0.1
Total liabilities	3'130	55.1	3'675	59.4
Total equity and liabilities	5'678	100.0	6'188	100.0

# **Geographic split**

### H1 sales CHF 2 284 m

in CHF m, % in local currency




# Regional headline

- Sales in the Americas were lower due to the divestment of the North American Land Oil business as well as force majeure declarations in the first quarter, despite the positive contribution from the Attapulgite integration
- EMEA sales were lower, as strong growth from Catalysts in the Middle East could not offset the impact of weak demand in Germany on Care Chemicals as well as Adsorbents & Additives
- Asia-Pacific sales declined slightly as the slow pace of recovery in China was most notable in Additives, while Catalysts grew




# EBITDA / EBIT Bridge First Half Year 2023


### **Group continuing operations** (CHF m)




### **Care Chemicals** (CHF m)



### Catalysis (CHF m)



### **Adsorbents & Additives** (CHF m)



# **ROIC** vs. increased cost of capital


## ROIC<sup>1</sup> in % 10.6 %<sup>3</sup> 9.9 % Cost of capital: 8.5 % - 7.7 %<sup>2</sup> 7.4 % 1.5 % 0.1 % (reported) (reported) 2019 2020 2021 2022 HY 2023 (restated) (LTM)

# Improvement drivers

- Organic growth
- Increasing operating margin
- Reducing nonoperating cost
- Improving capital turns


# Cost dynamics – lower year-onyear and sequentially

- Raw materials decreased year-on-year (sequential 6 %)
- Energy down year-on-year (sequential 20 %)
- Logistics lower year-on-year (sequential 22 %)



# Flat pricing – Volumes impacted by macro environment

- Recessionary economic environment in Q2
- Pricing flat (sequentially 1 %), Positive in CA and A&A,
   CC slightly down as formula/index-based prices adjusting
- Volumes year-on-year in CA + 25 %, CC 10 %, and A&A 17 %;
   Group 5 % vs. strong prior year
- Continued destocking and weak consumer and industrial demand
- Volumes sequentially 6 %



# Reporting aligned with new operating structure as of Q1 2023



## **Business Unit Care Chemicals (CC)**

Segments include Personal & Home Care, Crop Solutions, Industrial Applications, Base Chemicals, Oil Services, and Mining Solutions



## **Business Unit Catalysts (CA)**

Segments include Propylene, Specialties, Syngas & Fuels, Ethylene, and Biofuels & Derivatives



### **Business Unit Adsorbents & Additives (A&A)**

Segments include Adsorbents, Coatings & Adhesives, Plastics, and E-mobility & Electronics

**Key financial figures 2022** 

Sales CHF 2937 m 19.5 % EBITDA margin

Sales **CHF 989** m **9.4** % EBITDA margin

Sales CHF 1272 m 21.7 % EBITDA margin



# 2022 – Reflecting Business Unit Structure as of 1 Jan 2023

SALES and EBITDA reported & before exceptional items (b.e.i.)


in CHF m		Q1 2022			Q2 2022			Q3 2022			Q4 2022			FY 2022	
	Sales	EBITDA reported	EBITDA b.e.i.												
Care Chemicals <sup>1</sup>	758	149	151	740	142	140	725	144	144	714	138	143	2 937	573	578
margin		19.7 %	19.9 %		19.2 %	18.9 %		19.9 %	19.9 %		19.3 %	20.0 %		19.5 %	19.7 %
Catalysts <sup>2</sup>	185	14	14	232	13	14	262	30	31	310	36	39	989	93	98
margin		7.6 %	7.6 %		5.6 %	6.0 %		11.5 %	11.8 %		11.6 %	12.6 %		9.4 %	9.9 %
Adsorbents & Additives <sup>3</sup>	319	83	83	329	79	80	325	79	79	299	35	39	1 272	276	281
margin		26.0 %	26.0 %		24.0 %	24.3 %		24.3 %	24.3 %		11.7 %	13.0 %		21.7 %	22.1 %
Business Units Total	1 262	246	248	1 301	234	234	1 312	253	254	1 323	209	221	5 198	942	957
Corporate		- 26	- 10		- 18	- 24		- 33	- 12		- 55	- 18		- 132	- 64
Total Contin. Operations	1 262	220	238	1 301	216	210	1 312	220	242	1 323	154	203	5 198	810	893
margin		17.4 %	18.9 %		16.6 %	16.1 %		16.8 %	18.4 %		11.6 %	15.3 %		15.6 %	17.2 %

<sup>&</sup>lt;sup>1</sup> BU Care Chemicals includes former BA Care Chemicals and BU Oil & Mining Services; <sup>2</sup> BU Catalysts unchanged from former BA Catalysis; <sup>3</sup> BU Adsorbents & Additives includes former BU Functional Minerals and BU Additives



# Exposure to attractive consumer markets of around 50 %... with accelerating demand for sustainable products

Sales by end market (Q2 2023 LTM<sup>1</sup>)



<sup>&</sup>lt;sup>1</sup> Last Twelve Months (Q3 2022 – Q2 2023)

# **ESG – Clariant's Sustainability Transformation Commitment**

### Sustainability priorities

### **Fighting Climate Change**

Reducing our own carbon footprint and creating value for customers with low-carbon, high-performing solutions

### Zero Waste and Pollution

Eliminating waste and pollution from our operations and value chains



Safe and sustainable in everything we do



### **Social Value Creation**

Creating value for our employees, in our business networks, and in society as a whole


### **Increasing Circularity**

Products and solutions that enable reducing, reusing, and recycling

## Sustainable **Bio-economy**

Creating a sustainable bio-economy by protecting nature and maintaining high social standards

### Investment in operations & portfolio



### Sustainable operations

Future-proof our operations for a climateneutral, sustainable world



## **Sustainability-driven** portfolio change


Increase the safety and sustainability of our products and help our customers achieve their sustainability goals

# Clariant is well recognized as an industry leader by important ESG ratings and rankings

Status as of July 2023

Index / Ranking / Rating	Clariant score / Percentile rank or range	Status / Comments		First year of inclusion
Member of Dow Jones Sustainability Indices Powered by the S&P Global CSA	72 / 97 <sup>th</sup> percentile	DJSI Europe Member, Sustainability Yearbook 2023 member	Sustainability Yearbook Member 2022 S&P Global	2012
SUSTAINALYTICS	20.8 (Medium risk) / 94 <sup>th</sup> percentile	Leader (compared to industry peers)	Legend         Rank   Percentile           (1st ≠ Top Score)         Industry (Chemicals)           32 / 562   6th	2016
MSCI ∰	AA / Range: AAA to CCC	Second best score	22% 6% 8% 12% 18% 16% 16% CCC 8 88 888 A AA AAA	2015
ISS-oekom▶	B- / Top 10%	"Prime" status and industry leader	Corporate Responsibility Prime rated by cekom r o s o a r c h	2013
FTSE Russell	3.7 / 77 <sup>th</sup> percentile	Included in FTSE4 Good Index	FTSE4Good	2015
ecovadis	75 / 98 <sup>th</sup> percentile	-	-75 <sub>/10</sub>	2012
vigeoeiris	60 / 100 – "advanced"	Included in Ethibel and Euronext indices	EURONEXT Vige Quiris Noces EUROPE 120	2014
WCDP.	Climate: B / Range: A to D-	Above global average	A-B-Climate B-Water an	d Forests
DRIVING SUTVANDLE DOHOMES	- Water B- / Range: A to D-	Forests: above global average Water: below global average	c c	2013

# **Debt Maturity Profile as of 30 June 2023**



<sup>&</sup>lt;sup>1</sup> financial derivatives with positive fair values reported under other current assets

<sup>&</sup>lt;sup>2</sup> Green Bond as issued under Clariant Green Financing Framework

# **Calendar of Upcoming Corporate Events**

2023 2024

**30 October 2023** 

Third Quarter / Nine Month 2023 Reporting

9 April 2024

AGM 2024

28 July 2023

Second Quarter / First Half Year 2023 Reporting

**29 February 2024** 

Fourth Quarter / Full Year 2023 Reporting

# **The Executive Leadership Team**



Conrad Keijzer
Chief Executive Officer

### **Executive Leadership Team**

### **Executive Steering Committee**



Christian Vang
Business President
CC & Americas



Jens Cuntze
Business President
CA & APAC



Angela Cackovich
Business President
AA & EMEA



Bill Collins
Chief Financial
Officer



Tatiana Berardinelli Chief Human Resources Officer



Judith Bischof General Counsel



Richard Haldimann Chief Technology & Sustainability Officer



Chris Hansen
Chief Corp.
Development Officer

## **IR Contacts**



ANDREAS SCHWARZWÄLDER
Head of Investor Relations

Phone: +41 61 469 63 73

Email: <u>investor-relations@clariant.com</u>



MARIA IVEK
Senior Investor Relations Officer

Phone: +41 61 469 63 73

Email: <u>investor-relations@clariant.com</u>



**THIJS BOUWENS**Investor Relations Officer

Phone: +41 61 469 63 73

Email: <u>investor-relations@clariant.com</u>

